Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

VOR Biopharma's valuation surged with telitacicept, yet dilution risks and share structure uncertainty maintain volatility.

Candidates who participated in the UP BEd JEE 2025 Counselling Round 1 can now check their seat allotment result on the ...

Key Points GAAP earnings per share of $0.04 exceeded the consensus estimate of negative $0.08 for Q2 2025 No commercial revenue reported; company remains in pre-revenue phase with product launches ...

President Trump has ordered a “comprehensive internal review” of exhibitions and materials at several Smithsonian museums to ...

BIO-key International, Inc. Q2 2025 Earnings Conference August 13, 2025 10:00 AM ETCompany ParticipantsCecilia C.